The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
about
Understanding and targeting resistance mechanisms in NSCLC.Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors and Non-Small Cell Lung Cancer (NSCLC) - Advances in Molecular Diagnostic Techniques to Facilitate Targeted Therapy.Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.Significance and prognostic role of human epidermal growth factor receptor 2 and RAB1A expression in gastric cancer.Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.
P2860
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@ast
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@en
type
label
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@ast
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@en
prefLabel
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@ast
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@en
P2093
P2860
P1433
P1476
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma.
@en
P2093
Chang Young Lee
Eun Kyung Kim
Kyung A Kim
P2860
P304
P356
10.1371/JOURNAL.PONE.0171280
P407
P50
P577
2017-02-01T00:00:00Z